Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...

As a young girl in Kampala, Karmali Rashida would read stories about medicine and the human body. The deep curiosity about healing sparked something in her, a fascination with science that would one ...

Pharma giant AstraZeneca urged Britain to improve the environment for businesses in order to drive investment, days after it ...

The UK government has announced a shift in its nuclear energy policy to approve additional nuclear power plants across ...

This was the stock's second consecutive day of gains.

UK technical and strategic nuclear consultancy Equilibrion has been appointed by Northern Gas Networks (NGN) and Wales & West ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Hello, and welcome to Regeneron Pharmaceuticals' fourth quarter 2024 earnings conference call. My name is Tawanda, and I will be your operator for today's call. (Operator Instructions) Please note ...

DelveInsight's Peptide-drug Conjugate Market Insights report provides the current and forecast market analysis, individual ...

Report with the AI impact on market trends - The global biotech market size is estimated to grow by USD 805.6 billion from ...

DelveInsight's 'Dry Age-Related Macular Degeneration Pipeline Insight 2025' report provides comprehensive global coverage of ...